Company Profile
Moderna, Inc. Stock Price, News & Catalysts
- Ticker:
- MRNA
- Exchange:
- NASDAQ
- Sector:
- Nucleic Acid Drugs
- Location:
- United States
Stock performance
187.46 USD (-7.75%)
Close
Last updated: October 6, 2026
18.1B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, MRNA closed down 7.75% at $187.46. No new same-company headline was identified in the current news window.
Company overview
Messenger RNA Medicines Platform
Moderna is a biotechnology company built around messenger RNA medicines. Its platform combines mRNA sequence design, lipid nanoparticle delivery, automated research, clinical development, and large-scale manufacturing to create vaccines and therapeutics across infectious disease, oncology, and rare disease.
Commercial Respiratory Vaccines
The commercial portfolio is anchored by Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus. Moderna is extending this respiratory franchise through seasonal influenza and combination vaccines intended to address multiple respiratory viruses with a single injection.
Broad Infectious-Disease Pipeline
Beyond its marketed products, Moderna is developing vaccines against influenza, cytomegalovirus, norovirus, and other viral pathogens. The company uses a common platform and manufacturing infrastructure across these programs, allowing clinical and process-development knowledge to be reused across vaccine candidates.
Oncology and Individualized Therapies
Moderna's oncology portfolio includes intismeran autogene, an individualized neoantigen therapy being developed with Merck in combination with KEYTRUDA. The broader cancer pipeline applies mRNA to encode tumor-specific antigens, immune stimulators, and other proteins intended to generate or strengthen antitumor immune responses.
Rare-Disease Therapeutics
The company is also developing systemic mRNA therapeutics for inherited metabolic diseases, including programs designed to restore missing intracellular enzymes. These candidates extend the platform beyond prophylactic vaccines into repeat-dose medicines for genetically defined disorders.
Future catalysts
- FDA PDUFA decision for seasonal influenza vaccine candidate mFLUSIVA on August 5, 2026.
- Enrollment of an additional Phase 3 cohort for norovirus vaccine candidate mRNA-1403 following the interim analysis.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Moderna, Inc. (MRNA)?
Moderna, Inc. (MRNA) most recently closed at 187.46 USD, a -7.75% move versus the previous session.
What is the market cap of Moderna, Inc. (MRNA)?
Moderna, Inc. currently has a market capitalization of 18.1B USD on BioPharmSignal.
What does Moderna, Inc. do?
Messenger RNA Medicines Platform Moderna is a biotechnology company built around messenger RNA medicines. Its platform combines mRNA sequence design, lipid nanoparticle delivery, automated research, clinical development, and large-scale manufacturing to create vaccines and therapeutics across infectious disease, oncology, and rare disease. Commercial...
On which exchange is MRNA stock listed?
Moderna, Inc. (MRNA) is associated with NASDAQ, United States, Nucleic Acid Drugs.
What is COVID-19?
Commercial Respiratory Vaccines The commercial portfolio is anchored by Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus.
Which conditions is Moderna, Inc. targeting with COVID-19?
Moderna, Inc. is associated with oncology, cancer therapeutics, rare disease based on its company overview and current catalyst commentary.
How does Moderna, Inc. describe recent progress with COVID-19?
FDA PDUFA decision for seasonal influenza vaccine candidate mFLUSIVA on August 5, 2026. Enrollment of an additional Phase 3 cohort for norovirus vaccine candidate mRNA-1403 following the interim analysis.
What is intismeran?
Oncology and Individualized Therapies Moderna's oncology portfolio includes intismeran autogene, an individualized neoantigen therapy being developed with Merck in combination with KEYTRUDA.